Clinical trial
Therapy With Docetaxel and ZD1839 for Patients Who Have Advanced Breast Cancer
NCT00052169 · NSABP Foundation Inc, Other · Completed
Key facts
| NCT number | NCT00052169 |
|---|---|
| Title | Therapy With Docetaxel and ZD1839 for Patients Who Have Advanced Breast Cancer |
| Official title | A Phase 2, Multi-Center Trial of ZD1839 (IRESSA) in Combination With Docetaxel as First-Line Treatment in Patients With Advanced Breast Cancer |
| Lead sponsor | NSABP Foundation Inc, Other |
| Collaborators | AstraZeneca Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Breast Neoplasms |
| Intervention type | Drug |
| Interventions | ZD1839 in combination with docetaxel |
| Enrollment | 33 |
| Start date | Jan 1, 2003 |
| Completion | Sep 1, 2006 |
| First posted | Jan 27, 2003 |
| Last update posted | Dec 18, 2007 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: